These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22715557)

  • 1. Myelodysplastic syndromes: a challenging disease for patients and physicians.
    Somani N
    J Assoc Physicians India; 2012 Feb; 60():107-8, 113. PubMed ID: 22715557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of iron overload in myelodysplastic syndromes.
    Fenaux P; Rose C
    Blood Rev; 2009 Dec; 23 Suppl 1():S15-9. PubMed ID: 20116635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndromes: biology and treatment.
    Jädersten M; Hellström-Lindberg E
    J Intern Med; 2009 Mar; 265(3):307-28. PubMed ID: 19141095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current management of myelodysplastic syndromes].
    Vey N; Charbonnier A
    Rev Prat; 2010 Dec; 60(10):1416-9. PubMed ID: 21425543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
    Greenberg PL; Cosler LE; Ferro SA; Lyman GH
    J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
    Le Bras F; Sebert M; Kelaidi C; Lamy T; Dreyfus F; Delaunay J; Banos A; Blanc M; Vey N; Schmidt A; Visanica S; Eclache V; Turlure P; Beyne-Rauzy O; Guerci A; Delmer A; de Botton S; Rea D; Fenaux P; Adès L
    Leuk Res; 2011 Nov; 35(11):1444-8. PubMed ID: 21715006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of myelodysplastic syndromes in elderly patients.
    Sanchez JF
    Adv Ther; 2011 Mar; 28 Suppl 2():1-9. PubMed ID: 21431504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society.
    Meers S; Breems D; Bries G; Delforge M; Graux C; Ravoet C; Selleslag D; Noens L;
    Acta Clin Belg; 2013; 68(4):253-62. PubMed ID: 24455794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
    Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
    Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to treat MDS without stem cell transplantation.
    Gattermann N
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S30-6. PubMed ID: 19857591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.